Profile
Michael Braunagel is the founder of Affitech AS, which was founded in 1997.
He held the title of Director-Strategic Alliances & Licensing from 1997 to 2009.
Dr. Braunagel's former job was as Senior Director-Strategic Alliances & Licensing at Affitech A.
Former positions of Michael Braunagel
Companies | Position | End |
---|---|---|
Affitech AS /Old/
Affitech AS /Old/ Miscellaneous Commercial ServicesCommercial Services Affitech AS discovers and develops human therapeutic antibodies. It focuses on molecule and cell based antibody discovery. The company was founded by Martin Welschof, Ole Jorgen Marvik, and Michael Braunagel in 1997 and is headquartered in Oslo, Norway. | Founder | 2009-06-15 |
Affitech A/S
Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Affitech AS /Old/
Affitech AS /Old/ Miscellaneous Commercial ServicesCommercial Services Affitech AS discovers and develops human therapeutic antibodies. It focuses on molecule and cell based antibody discovery. The company was founded by Martin Welschof, Ole Jorgen Marvik, and Michael Braunagel in 1997 and is headquartered in Oslo, Norway. | Commercial Services |
Affitech A/S
Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Stock Market
- Insiders
- Michael Braunagel